News & Updates
Filter by Specialty:
Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
27 Nov 2022
A recent study has demonstrated the safety and efficacy of bulevirtide (BLV) monotherapy for 48 weeks in difficult-to-treat patients with hepatitis delta virus (HDV)-related compensated cirrhosis and clinically significant portal hypertension (CSPH).
Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
27 Nov 2022CT angiography may increase potential EVT recipients for acute ischaemic stroke
27 Nov 2022
byRoshini Claire Anthony
Using collateral flow findings, as seen on computed tomographic (CT) angiography, may widen the population who can undergo late endovascular treatment (EVT) for acute ischaemic stroke (AIS), according to findings of the MR CLEAN-LATE trial.
CT angiography may increase potential EVT recipients for acute ischaemic stroke
27 Nov 2022Myocarditis, pericarditis not uncommon with mRNA-1273 COVID-19 vaccines
26 Nov 2022
Although the incidence of myocarditis or pericarditis following mRNA COVID-19 vaccination is low, a two- to threefold higher likelihood is seen among individuals who received mRNA-1273 compared to BNT162b2 vaccine, reveals a study.